Vidcast: https://www.instagram.com/drhowardsmithreports/reel/DH9MacqsZKC/

A novel, bivalent RSV vaccine provides lasting protection against respiratory syncytial viral disease over two rather than only one season. This the result of a phase 3 so-called RENOIR trial that tested 36,862 participants 60 to over 80 years of age at 241 sites in 7 countries. Helmed by University of Rochester infectious disease researchers, it was just reported in the Clinical Infectious Diseases journal.

The vaccine, developed by Pfizer, contains both RSV-A and RSV-B antigens. Tested against a placebo, the vaccine provided 88.9% protection from one month after immunization through the first season and 77.8% protection through the second season. The already available monovalent RSV vaccines from both Pfizer and GSK are verified protective for only one season.

This bivalent vaccine, named RSVPreF, can be safely and effectively co-administered with both the influenza vaccines and the CoVid vaccines. That provides a comprehensive shield against that trio of potentially deadly viral respiratory diseases in only one visit to your medical team or neighborhood pharmacy.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf061/8006665?login=false

https://www.medscape.com/viewarticle/bivalent-rsv-vaccine-shows-sustained-efficacy-and-safety-2025a10006y0

#RSV #bivalent #vaccine #renoir #pfizer #universityrochester

A Longer-Lasting RSV Vaccine

Dr. Howard Smith Reports